Key result
In anesthetized rats, inhibition of NO synthesis with L-NAME downregulated propranolol-sensitive beta-adrenoceptor activity and upregulated propranolol-insensitive beta-adrenoceptor activity.
Why the study?
Does inhibition of NO synthesis alter the relative contribution of propranolol-sensitive and -insensitive beta-adrenoceptors to the hemodynamic responses elicited by isoprenaline in anesthetized rats?
Does inhibition of NO synthesis alter the relative contribution of propranolol-sensitive and -insensitive beta-adrenoceptors to the hemodynamic responses elicited by isoprenaline in anesthetized rats?
Inhibition of NO synthesis in rats appears to downregulate propranolol-sensitive beta-adrenoceptors and upregulate propranolol-insensitive beta-adrenoceptors.
Hypothesis-generating in rats; leaves open whether NO inhibition shifts beta-adrenoceptor balance in human cardiovascular disease.
The beta-adrenoceptor agonist, isoprenaline, elicits vasodilation and tachycardia in anesthetized rats via activation of propranolol-sensitive beta1- and beta2-adrenoceptors and also by propranolol-insensitive beta1- and beta3-adrenoceptors. The aim of this study was to determine whether the relative contribution of propranolol-sensitive and -insensitive beta-adrenoceptors to the changes in heart rate (HR) and vascular resistances elicited by isoprenaline is altered after blockade of nitric oxide (NO) synthase, in pentobarbital-anesthetized rats. The hemodynamic responses elicited by isoprenaline (0.1 and 0.5 microg kg(-1), i.v.) were determined before and after injection of saline or the NO synthase inhibitor, N(G)-nitro-L-arginine methylester (L-NAME, 50 micromol kg(-1), i.v.), and again after injection of the beta1- and beta2-adrenoceptor antagonist, propranolol (1 mg kg(-1), i.v.). The responses elicited by the above doses of isoprenaline were also determined before and during infusion of the alpha1-adrenoceptor agonist, phenylephrine (3 microg kg(-1) min(-1), i.v.), and again 15-20 min after injection of propranolol (1.0 mg kg(-1), i.v.). Both doses of isoprenaline elicited tachycardia and reductions in vascular resistances. Propranolol eliminated the responses elicited by the lower dose of isoprenaline and substantially diminished the responses elicited by the higher dose of the beta1-, beta2- and beta3-adrenoceptor agonist. The maximal vasodilator responses elicited by both doses of isoprenaline were not diminished whereas the maximal increases in HR were higher after injection of L-NAME. The ability of propranolol to diminish the hemodynamic actions of isoprenaline was substantially diminished in L-NAME-treated rats, whereas propranolol retained its potency in rats that received an equi-pressor infusion of the alpha1-adrenoceptor agonist, phenylephrine. The finding that the maximal vasodilator responses elicited by isoprenaline were not diminished by L-NAME suggests that the vasodilation elicited by this drug was due to direct activation of beta-adrenoceptors on vascular smooth muscle and that the full compliment of isoprenaline-sensitive receptors was not changed after inhibition of NO synthesis. However, these results suggest that the activities of propranolol-sensitive beta-adrenoceptors are downregulated, whereas propranolol-insensitive beta-adrenoceptors are upregulated upon the loss of exposure to endothelial nitrosyl factors.
No takes yet. Share an insight, caveat, or question.
Whalen et al. (2006) studied this question. Isoprenaline vs. Before and after L-NAME and propranolol was evaluated on Hemodynamic responses (heart rate and vascular resistances). In anesthetized rats, inhibition of NO synthesis with L-NAME downregulated propranolol-sensitive beta-adrenoceptor activity and upregulated propranolol-insensitive beta-adrenoceptor activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: